Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on December 10, 2021. The report details the entry into a material definitive agreement to establish an "At The Market" (ATM) equity offering program.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial data relates to the new capital raising facility:
- Maximum Offering Size: Up to $15,000,000 in aggregate gross proceeds.
- Agent: Ladenburg Thalmann & Co. Inc.
- Commission: Up to 3.0% of gross sales proceeds.
- Legal Expense Reimbursement: Up to $75,000 for counsel fees plus up to $3,000 per calendar quarter for ongoing disbursements.
Material Changes
The material change reported is the execution of the ATM Offering Agreement on December 10, 2021. This agreement allows the company to sell shares of its common stock through the agent at prevailing market prices. The offering is based on an effective shelf registration statement (Form S-3) filed on November 22, 2021.
Outlook, Risks, and Management Commentary
Terms and Termination: The offering program will terminate on the earlier of December 10, 2024, or upon termination of the agreement by either party. The company is not obligated to sell any shares under this agreement.
Risks and Contingencies: The filing notes that the sale of shares is subject to market conditions and the company's discretion regarding price, time, and size limits. The report explicitly states it does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of selling up to $15 million in equity.
- Confirm the status of the underlying Form S-3 shelf registration (File No. 333-261283).
- Monitor future 8-K filings or quarterly reports for actual sales volumes and proceeds generated under this ATM program.
- Review the full text of the At The Market Offering Agreement (Exhibit 10.1) for specific termination clauses and conditions.